Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT
A Contract Award Notice
by BELFAST HEALTH AND SOCIAL CARE TRUST
- Source
- Find a Tender
- Type
- Contract (Goods)
- Duration
- not specified
- Value
- £3M
- Sector
- HEALTH
- Published
- 30 Jun 2022
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
Northern Ireland:
1 buyer
1 supplier
Description
Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT
Award Detail
| 1 | Advanced Accelerator Applications UK & Ireland (London)
|
Award Criteria
| price | _ |
CPV Codes
- 33000000 - Medical equipments, pharmaceuticals and personal care products
Legal Justification
No other reasonable alternative or substitute exists for this procurement and the absence of competition is not a result of the artificial narrowing of the parameters of the procurement. Lutetium (177Lu) oxodetreotide (Lutathera) is a licensed radiopharmaceutical for the treatment of unresectable or metastatic, progressive, well-differentiated somatostatin receptor positive gastro-entero-pancreatic neuroendocrine (GEP) tumours in adults. The supplier, Advanced Accelerator Applications (AAA), holds the unique patent and licence for this product. This is the only licenced Peptide Receptor Radionuclide Therapy (PRRT) in Europe
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. **
Reference
- ocds-h6vhtk-034401
- FTS 017908-2022